MIMO Biosciences

mimobiosciences.com ↗ ·Pamplona ·Seed

MIMO Biosciences is a contract research organization (CRO) specialized in hematology and immuno-oncology, spun out of Cima Universidad de Navarra in February 2024 after twelve years of research in the hemato-oncology lab of Dr. José Ángel Martínez-Climent. It provides preclinical research services built on proprietary animal models (syngeneic models, GEMMs, PDX and humanized xenografts) that faithfully reproduce the genetic alterations of multiple myeloma, lymphomas and other hematological malignancies, serving pharma and biotech drug-development programs. It closed a first capital increase in November 2024 with Sanitas and private investors, and won the 2025 CaixaBank EmprendeXXI award as the highest-potential startup in Navarra. It is based in Pamplona (Navarra).

Founded

2024

Founders

Total funds raised

—

SectorsBiotech, Preclinical CRO, Oncology, Hematology, Life Sciences Start-up MapHealthtech & Bio › R&D tools & software for life sciences

Suggest a correction

Founders

José Ángel Martínez-Climent

Founder & Chief Scientific Officer

Ricardo Pérez Merino

CEO

Global models 4

Biocytogen

China · www.biocytogen.com ↗

Preclinical CRO built on its own genetically engineered and humanized mouse models, selling efficacy studies in oncology and immuno-oncology to pharma and biotech, as MIMO does.

~$250MComparable

GemPharmatech

China · www.gempharmatech.com ↗

Earns money from a large proprietary library of GEMM and humanized mouse models plus in-vivo pharmacology services for drug developers, the same model-plus-services approach as MIMO.

~$200MComparable

Crown Bioscience

United States · www.crownbio.com ↗

Oncology preclinical CRO built on proprietary PDX, syngeneic and hematological tumour models, running efficacy studies for pharma; it was venture-backed before JSR bought it.

~$40MComparable

Certis Oncology Solutions

United States · www.certisoncology.com ↗

Venture-backed oncology CRO that sells preclinical studies built on its own patient-derived tumour models, including hematological cancers, to drug developers.

~$20MComparable